Analysts expect the Nashville, Tennessee-based company to report a quarterly loss at 1 cent per share, versus a year-ago loss ...

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $3 from $4 and keeps a Buy rating on the ...

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the company announced a “long-awaited” manufacturing agreement with ...

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Cytokinetics (CYTK – Research Report), with a ...

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a price target of $38.00. The company’s ...

Mayank Mamtani; Analyst; B. Riley Securities, Inc. Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price target of $4.00. The company’s shares closed ...

Q4 2024 Management View CEO Michael Weiss highlighted the strong full-year 2024 U.S. revenue of $310 million for BRIUMVI, exceeding initial guidance and reflecting the therapy's value in treating ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TG Therapeutics (TGTX – Research Report), ...

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the company announced a ...

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I will now turn the call ...